logo
Brunswick students sent scientific instrument into space on Blue Origin

Brunswick students sent scientific instrument into space on Blue Origin

Yahoo22-04-2025
Apr. 21—A little piece of Brunswick entered space last week onboard the all-female Blue Origin rocket flight.
Partnering with nonprofit Teachers in Space, Karin Paquin's middle school students at St. John's Catholic School designed an experiment that flew on the New Shepherd rocket during the historic launch on April 14.
The CubeSat, a type of small satellite, flew with other experiments — including many designed by students — in the payload of the rocket. It had also been on an unmanned flight leading up to the one captained by Lauren Sanchez.
Students proposed hypotheses and schematics and selected sensors for the CubeSat. Their experiment measured temperature, UV radiation and other environmental conditions in the cabin as the rocket launched into suborbital space.
Fiona Sharp, now a freshman at Brunswick High School, helped design the Blue Origin CubeSat last year when she was in eighth grade at St. John's. She programmed sensors that went into the Blue Origin experiment, including one that measured radiation.
"There's really no words to describe it; it was just surreal," Sharp said. "It's crazy to see something that you touched with your own hands and put so much time into fly."
St. John's students watched the launch live at school last week.
"It was really really cool having something that kids we knew built, and it was on a flight with all of these influential women," said seventh grader Aria Golletti, who didn't work on the Blue Origin experiment but is working on St. John's next space project now.
The hands-on experience shows students that "everyone can do science," Paquin said. It was possible through a grant Blue Origin provided to Teachers in Space, she added.
"Companies like (Blue Origin) make experiences for my students possible, because this is not something that a teacher or a small school could afford, so that's pretty exciting — companies that put education first, knowing eventually, we're going to have to fill positions," Paquin said. "And so how do you get kids started?"
Sharp said her experience in Paquin's class helped solidify her love for science, and taught her the importance of trial and error.
"Just because you don't get the results you want back the fist time, you should keep experimenting and maybe try something else," Sharp said.
Paquin's science classes over the years have had several experiments onboard space flights. She said that the Maine Space Grant Consortium, Teachers in Space and Space for Teachers have been invaluable resources in helping bring space education to Brunswick and beyond.
Work from students at St. John's will also be on board a Zero-G flight in May, on which Paquin will be a passenger.
"The coding was tough," said seventh grader Jesse Davis, who worked on the upcoming experiment. "I was not totally sure what I was doing, but with lots of help, I got through."
Zero-G planes, or reduced gravity aircrafts, simulate the feeling of weightlessness and are used for astronaut training, research flights and tourism. Paquin went on one such research flight two years ago.
"All of a sudden, you just feel weightless," Paquin said about her experience.
Some former students have taken their research even further by competing in the University of Southern Maine CubeSat Design Competition. St. John's students Wesley Agnor and Gabriel Grondin placed first in the competition's middle school category last year.
Paquin will also lead workshops this summer on space education at the CS Summer of Fun conference in Bangor.
Copy the Story Link
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Yahoo

time2 days ago

  • Yahoo

Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that Nature Medicine (IF: 58.7) has published the results of the Phase 1 clinical study of IBI343, an innovative anti-CLDN18.2 ADC, for the treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma[Link]. Publication in this leading international academic journal indicates the strong recognition of the therapy's clinical potential and marks another significant milestone in China's progress in developing novel anti-tumor medications. Based on the study findings, a multi-regional Phase 3 clinical trial (G-HOPE-001, NCT06238843) was launched in 2024 to further evaluate IBI343 as a safe and effective treatment option for patients with advanced G/GEJ AC. Gastric cancer remains one of the most common malignant tumors in the world. According to the GLOBOCAN 2022 statistics, it ranks as the fifth most common malignant tumor and the fifth leading cause of cancer-related death globally, with an estimated 970,000 new cases and 660,000 deaths annually. Each year, China reports 359,000 new cases and 260,000 deaths from gastric cancer, representing 37.0% and 39.4% of global totals, respectively, highlighting a significant unmet medical need. CLDN 18.2 is a tight junction protein expressed in differentiated epithelial cells on the gastric mucosa under normal physiological conditions. Previous studies have revealed that Claudin18.2 is highly expressed in multiple types of cancer, including gastric cancer (60-80%), pancreatic cancer (50%), esophageal carcinoma (30-50%), and lung cancer (40-60%). Targeting CLDN18.2 with monoclonal antibodies (mAbs) and ADCs represents a promising new approach for treating gastric cancer. This published study is a global, multicenter Phase 1 clinical trial ( identifier: NCT05458219) designed to evaluate the safety, tolerability and preliminary efficacy of IBI343 in patients with advanced solid tumors. Between October 26, 2022, and June 30, 2024, a total of 116 subjects with advanced G/GEJ adenocarcinoma were enrolled to receive IBI343 monotherapy (8 in escalation and 108 in expansion). IBI343 has demonstrated encouraging tumor response and survival benefit The study analyzed the efficacy data of evaluable subjects with high expression of CLDN18.2 (≥75% tumor cells with membranous staining intensity ≥2+ by IHC), in the two dose groups of 6 mg/kg and 8 mg/kg. At 6 mg/kg (N=31), 15 patients had partial responses (PR) including 9 patients with confirmed PRs and 1 patient awaiting confirmation. The confirmed ORR was 29.0% (95% CI: 14.2-48.0) and the disease control rate (DCR) was 90.3% (95% CI: 74.2-98.0). In 9 patients with confirmed response, the median duration of response (DoR) was 5.6 months (95% CI: 2.8-7.0). The median follow-up was 10.6 months (95% CI: 9.7-11.5) for PFS and OS. The median PFS was 5.5 months (95% CI: 4.1-7.0). OS data was not mature with the current median OS of 10.8 months (95% CI: 6.8-NC). After data cutoff, response of the remaining 1 patient was confirmed on July 26, 2024 and the confirmed ORR was updated to 32.3% (95% CI: 16.7-51.4). At 8 mg/kg (N=17), 17 patients with high expression of CLDN 18.2 were evaluable. Among them, 9 patients had PRs including 8 patients had confirmed PR. The confirmed ORR 47.1% (95% CI: 23.0-72.2), and the DCR was 88.2% (95% CI: 63.6-98.5). In eight patients with confirmed response, the median DoR was 5.7 months (95% CI: 2.7-NC). Of all G/GEJ adenocarcinoma patients with high CLDN18.2 expression treated at 8 mg/kg (N=19, including 1 patient from dose escalation and 18 patients from dose expansion), the median follow-up was 8.1 months (95% CI: 7.6-8.5) for PFS and OS. The median PFS was 6.8 months (95% CI: 2.8-7.5), and the median OS was not reached with events occurred in 36.8% patients. IBI343 also demonstrated superior safety Among all patients with G/GEJ adenocarcinoma (n=116, including 8 patients with gastric cancer from the dose escalation phase), 66.4% patients (77/116) had ≥3 grade TEAEs. The most common ≥3 grade TEAEs (≥35%) were neutrophil count decreased (28.4%), white blood cell count decreased (25.9%), and anemia (16.4%). There were very few grade ≥3 gastrointestinal adverse events, including only 1.7% of grade ≥3 nausea. No interstitial lung disease of any grade was reported. Treatment-related toxicity was alleviated with adequate supportive treatment, and the overall safety was tolerable. Integrated pharmacokinetics (PK), exposure-response, safety, and efficacy data supported 6 mg/kg Q3W as the recommended Phase 2 dose (RP2D) of IBI343. This provides support for the conduct of subsequent Phase 3 trial, suggesting that IBI343 may become a new treatment option for patients with gastric cancer in the future. Professor Lin Shen, Corresponding Author, Leading Principal Investigator, from Beijing Cancer Hospital, said, "Following the eras of chemotherapy, targeted therapy and immunotherapy, ADCs have opened a new frontier in the treatment of gastrointestinal tumors. IBI343 is a new generation of Fc-silent anti-CLDN18.2 ADC that has shown encouraging clinical benefits and low gastrointestinal toxicity in Phase 1 studies. We look forward to the results of the Phase 3 study comparing IBI343 with standard treatment, aiming to ultimately reshape clinical practice, transform treatment paradigms, and usher in a new chapter in precision medicine." Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent Biologics, said, "There is a huge unmet clinical need for the treatment of advanced gastric cancer. The Phase 1 study results of IBI343 in advanced gastric and gastroesophageal junction adenocarcinoma, now published in the top international journal, Nature Medicine, further verify the clinical value of IBI343 in this population. We will work with researchers worldwide to advance the multi-regional Phase 3 clinical trial (G-HOPE-001), with the goal of establishing a new paradigm in clinical diagnosis and treatment and ultimately benefiting gastric cancer patients around the world. We are also exploring the therapeutic potential of IBI343 in pancreatic cancer and other indications." About Gastric/ Gastroesophageal Junction Adenocarcinoma Gastric cancer is one of the most prevalent malignant tumors worldwide and a leading cause of cancer-related deaths globally. The 5-year survival rate of patients with metastatic gastric cancer is less than 5%[i]. China and Japan have the highest incidence rates of gastric cancer[ii]. Currently, the standard-of-care treatments for patients with advanced metastatic gastric cancer include a chemotherapy combination of fluoropyrimidine and platinum, as well as immune checkpoint inhibitor therapy. However, systemic therapy has limited efficacy in advanced gastric cancer. In particular, the prognosis for patients with third-line or higher gastric cancer is usually poor, with fewer treatment options and shorter survival expectations. The median survival time for these patients is only about 0.5 year[iii]. Claudin, a member of the tight junction molecule family, is a key structural and functional component of epithelial tight junctions. Among them, CLDN18.2 is normally buried in gastric mucosa, but the development of malignancy leads to disruption of tight junctions and exposure of CLDN18.2 epitopes on the membrane of tumor cells[iv]. CLDN18.2 is expressed in up to 80% of patients with gastric cancer. About IBI343(Anti CLDN18.2 ADC) IBI343 is a recombinant human anti-CLDN18.2 monoclonal antibody-drug conjugate (ADC) developed by Innovent Biologics. It specifically binds to the tumor cells expressing CLDN18.2, triggering CLDN18.2-dependent internalization of the ADC. Once inside the cell, the cytotoxic payload is released, resulting in DNA damage and ultimately apoptosis of the tumor cells. The released drug can also diffuse across the plasma membrane to reach and kill neighboring cells, resulting in a "bystander killing effect". As an innovative TOPO1i ADC, IBI343 has demonstrated tolerable safety and encouraging efficacy signals in this Phase 1 clinical studies. The therapeutic potential of IBI343 is currently being explored in tumor types such as gastric cancer and pancreatic cancer. The multi-regional Phase 3 clinical trial of IBI343 for advanced gastric / gastroesophageal junction adenocarcinoma is now recruiting patients (G-HOPE-001, NCT06238843). The relevant indication has been granted Breakthrough Therapy Designation (BTD) by China's NMPA . The multi-regional Phase 1 clinical trial of IBI343 for advanced pancreatic ductal adenocarcinoma is also enrolling patients (NCT05458219). This indication has received Fast Track Designation (FTD) from the U.S. FDA and been granted BTD by China's NMPA. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: Biologics does not recommend the use of unapproved drugs/indications. injection (Cyramza®), selpercatinib capsules (Retsevmo®) and pirtobrutinib tablets (Jayprica®) were developed by Eli Lilly and Company Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics, Inc. ("Innovent" or "Company"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. References [i] Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. Anticancer Res. May 2014;34(5):2079-85 [ii] Xu B, Wang JM. Epidemiological study of gastric cancer[J]. Chin J Cancer Prev Treat, 2006,13(1): 81-87. [iii] Chan WL, Lam KO, So TH, et al. Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review. Ther Adv Med Oncol. 2019;11:1758835919859990. [iv] Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624-7634. View original content: SOURCE Innovent Biologics

Why Oprah Winfrey 'would never' go to space like best friend Gayle King
Why Oprah Winfrey 'would never' go to space like best friend Gayle King

USA Today

time2 days ago

  • USA Today

Why Oprah Winfrey 'would never' go to space like best friend Gayle King

Oprah Winfrey isn't joining her bestie Gayle King by going to space any time soon. The ex-"Oprah Winfrey Show" host got candid on the July 16 episode of the SiriusXM show "Let's Talk Off Camera with Kelly Ripa" about why she skipped going on the infamous Blue Origin flight in April with her BFF. "I would never do it, but I became very interested in the whole process," Winfrey said. The Oprah's Book Club creator told Ripa that she was "just so proud to be there for" King, adding she was "relieved" that the "CBS Mornings" host went to space, "because if she'd asked one more time, 'What should I do? Do you think I should go?' I, from the beginning, was like, 'You should do it.'" Winfrey also revealed that she told King not to "let Katy Perry come down and say, 'It was really great fun.'" Kelly Ripa shuts down Mark Consuelos' 'repulsive' morning habit For the mission, King joined pop star Perry and billionaire Amazon founder Jeff Bezos' now-wife and author Lauren Sánchez Bezos along with three others for the first all-female flight to space in decades. However, the flight from Bezos-backed exploration company Blue Origin garnered widespread criticism. Still, Winfrey encouraged King to adventure. "You're going to be really saying, 'I should have done it,'" she recalled telling King. "The minute somebody says, 'Oh my God, like a life changing experience,' you're going to go, 'Oh, I should have done it.'" Oprah says July book club pick hooked her 'until the very last shocking sentence' The "Oprah Winfrey Show" star confessed that she knew it was time to leave her eponymous daytime talk show, which ended in 2011, when her team suggested they send an audience to space. "I remember going into a meeting and someone saying, 'I think what we should do is try to get people on a spaceship, or we should be able to take an audience or some audience members up on a spaceship,'" Winfrey said. Oprah Winfrey tells Kelly Ripa not to 'walk away' from 'Live' talk show After making the admission, Winfrey gave her fellow talk show host a word of advice and told her that "it's not time for you to step away" from "Live," which Ripa hosts with husband and actor Mark Consuelos, because "you have fun and it's easy and it's light enough. And serious enough when it needs to be, and it's not a grind." The "Oprah Podcast" host said that she loved hosting her own show, but it was different than Ripa's because the "Oprah" show dealt with heavier topics, sharing with the "All My Children" alum that "the nature of what we were doing every day became just so hard." Gayle King on 'disrespectful' space backlash, celebrity friends 'throwing shade' "Don't let go of the platform that you have. Do not do it. Don't even consider it," Winfrey said. "Because I feel that the reach that you have, the audience that you've built, the family that you've created – both inside the studio and in the rest of the world – is really more vital and important now than ever before."

SpaceX launches Amazon's Starlink-rival satellites.
SpaceX launches Amazon's Starlink-rival satellites.

The Verge

time2 days ago

  • The Verge

SpaceX launches Amazon's Starlink-rival satellites.

Posted Jul 16, 2025 at 6:56 AM UTC SpaceX launches Amazon's Starlink-rival satellites. Amazon's third batch of Project Kuiper satellites have launched into space on Elon Musk's Falcon 9 rocket. Jeff Bezos plans to light up his space Internet service later this year with help from launch partners ULA, Arianespace, and yes, his own Blue Origin. The Kuiper constellation will eventually consist of more than 3,200 LEO satellites, less than half of what Starlink already has operating, with more competitors to come. Watch Falcon 9 launch the @ProjectKuiper KF-01 mission to orbit [

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store